Edgar Filing: Ohr Pharmaceutical Inc - Form 4

Form 4	cal Inc										
January 11, 2016								OMB A	PPROVAL		
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION											
Check this box if no longer subject to	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section								3235-0287 January 31, 2005 average		
Section 16. Form 4 or Form 5 obligations may continue. <i>See</i> Instruction 1(b).									urs per 0.5		
(Print or Type Respon	nses)										
1. Name and Address of Reporting Person <u>*</u> HIRSCHMAN ORIN			2. Issuer Name and Ticker or Trading Symbol Ohr Pharmaceutical Inc [OHRP]				5. Relationship of Reporting Person(s) to Issuer				
(Last) ((First) (I					. ,	(Ch	eck all applicabl	x all applicable)		
C/O OHR PHARMACEUTICAL, INC., 800 THIRD AVENUE, 11TH FLOOR			(Month/Day/Year) 01/07/2016				X_ Director10% Owner Officer (give titleOther (specify below) below)				
(Street) 4. If Amendment, D Filed(Month/Day/Yea NEW YORK, NY 10022) Applicable Line) _X_ Form filed by C			y One Reporting P	int/Group Filing(Check Dne Reporting Person Iore than One Reporting			
(City) (State)	(Zip)	Tab	le I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned		
	nnsaction Date th/Day/Year)	Execution any	ed Date, if	3. Transactio Code (Instr. 8) Code V	4. Securit nAcquired Disposed (Instr. 3, 4	ies (A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect		
Reminder: Report on	a separate line	e for each cl	ass of sec	urities bene	Perso inform requir	ns who res nation cont red to respo lys a currer	or indirectly. pond to the colle ained in this forr ond unless the fo ntly valid OMB co	n are not orm	SEC 1474 (9-02)		
	Tab					posed of, or convertible s	Beneficially Owne securities)	d			
1. Title of 2.	3. Trans	action Date	3A. Dee	emed	4.	5. Number	of 6. Date Exerc	isable and	7. Title and Amount of		

Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative

Expiration Date

Edgar Filing: Ohr Pharmaceutical Inc - Form 4

Security (Instr. 3)			ny Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Year)		(Instr. 3 and 4)				
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	\$ 5.14	01/07/2016		А	60,000	<u>(1)</u>	01/06/2021	Common Stock	60,000			
Reporting Owners												
Reporting Owner Name / Address		R	elationship	s								
		Director 10%	Owner (Officer Other								
HIRSCHMAN ORIN C/O OHR PHARMACEUTICAL, INC. 800 THIRD AVENUE, 11TH FLOOR NEW YORK, NY 10022			Х									
Signa	tures											
/s/ Orin												
Hirschma	n	01/11/2016										
<u>**</u> Signat Reporting		Date										

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 1/3 of the shares of common stock subject to the stock option became exercisable immediately, and 1/3 of the shares of common stock subject to the stock option will become exercisable on each of January 7, 2017 and January 7, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

S (.